Previous 10 | Next 10 |
Smith+Nephew introduces first of its kind handheld digital tensioning device for robotically-enabled total knee arthroplasty PR Newswire LONDON , April 24, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today int...
New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques PR Newswire LONDON , March 23, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the gl...
Smith+Nephew to highlight procedural innovations in Sports Medicine during AAOS 2023 Annual Meeting PR Newswire LONDON , March 8, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN) (NYSE:SNN), the global medical technology company, today announces it will showcase its la...
Smith+Nephew unveils 'Precision in Motion' for its Orthopaedics Arthroplasty portfolio at AAOS 2023 Annual Meeting PR Newswire An uncompromising commitment to freedom of movement LONDON , March 7, 2023 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), th...
Smith+Nephew Sports Medicine advances procedural innovation by launching the QUADTRAC™ Quadriceps Tendon Harvest Guide System and expanded family of ULTRABUTTON™ Adjustable Fixation Devices for ACL reconstruction PR Newswire LONDON , March 7, 2023 /...
Smith+Nephew's VISIONAIRE™ Patient-Specific Instrumentation shown to improve outcome measures for total knee arthroplasty compared with conventional instrumentation PR Newswire LONDON , March 6, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), th...
Summary Enovis came up a little short with revenue and margins for both the fourth quarter of 2022 and guidance for 2023. The Reconstructive segment is performing well, with growth in U.S. hips, knees, and extremities that was well ahead of the group. The Prevention & Recovery b...
Summary Smith & Nephew saw flat top-line growth, declines in earnings and CFFO relative to FY21. Management has instilled a new 12-point plan in order to drive performance from FY23 onwards. It is now a matter of execution, and we rate SNN a hold at 24x earnings, in-line with th...
Summary Company reports top-line growth in Q4. Innovation & operational leverage finally turning the screw here. Shares remain cheap. We see higher prices coming for the stock in 2023. Intro We wrote about Smith & Nephew plc ( SNN ) in July of last ...
Summary Smith & Nephew plc's fourth quarter results were mixed; Ortho is still lagging its rivals, but Sports Medicine & ENT and Advanced Wound Care outperformed. The company has the technology to be more competitive in ortho and gain share in major joints and extremities, but w...
News, Short Squeeze, Breakout and More Instantly...
Smith & Nephew SNATS Inc. Company Name:
SNN Stock Symbol:
NYSE Market:
Smith & Nephew SNATS Inc. Website:
2024-07-24 05:15:02 ET Deutsche Bank analyst issues BUY recommendation for SNN on July 24, 2024 04:31AM ET. SNN was trading at $28.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 - Hold reco...
Engineered for precision, confidence and efficiency in surgery - and compatible with the CORI ◊ Surgical System Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance for its new CATALYSTEM Primary Hip System fro...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announces its Orthopaedics for All initiative – a global advisory board established to amplify diversity by building equity, breaking biases, and inspiring inclusion for individuals wishing to pursue a career in ort...